Venezuela (Bolivarian Republic of)Tuberculosis profile
Population  2016 32 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.71 (0.71–0.71) 2.2 (2.2–2.3)
Mortality (HIV+TB only) 0.25 (0.18–0.33) 0.79 (0.57–1)
Incidence  (includes HIV+TB) 10 (7.8–13) 32 (25–41)
Incidence (HIV+TB only) 1.2 (0.87–1.5) 3.7 (2.7–4.7)
Incidence (MDR/RR-TB)** 0.41 (0.23–0.58) 1.3 (0.73–1.8)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.64 (0.48–0.8) 3.1 (2.3–3.9) 3.8 (2.8–4.7)
Males 0.72 (0.54–0.9) 5.8 (4.3–7.2) 6.5 (4.9–8.1)
Total 1.4 (1–1.7) 8.9 (6.7–11) 10 (7.8–13)
TB case notifications, 2016  
Total cases notified 8 542
Total new and relapse 8 197
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 63%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.1 (0.07–0.12)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 585 11%
          - on antiretroviral therapy 485 83%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  290
(170–400)
Estimated % of TB cases with MDR/RR-TB 2.9% (1.4–4.5) 13% (6.7–20)  
% notified tested for rifampicin resistance 4% 27% 487
MDR/RR-TB cases tested for resistance to second-line drugs   49
Laboratory-confirmed cases MDR/RR-TB: 59, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 57, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 83% 7 133
Previously treated cases, excluding relapse, registered in 2015 77% 142
HIV-positive TB cases registered in 2015 81% 589
MDR/RR-TB cases started on second-line treatment in 2014 67% 33
XDR-TB cases started on second-line treatment in 2014 100% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (97–100)
TB financing, 2017  
National TB budget (US$ millions) <1
Funding source: 99% domestic, 1% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data